AI in Medical Affairs: Emerging Platforms, Governance Challenges, and the Future of Scientific Engagement

Artificial intelligence is rapidly transforming medical affairs from a primarily reactive support function into a proactive, intelligence-driven strategic capability. Across the pharmaceutical and biotechnology industries, medical affairs organizations are increasingly evaluating AI-powered platforms to support scientific exchange, medical information delivery, KOL engagement, congress intelligence, field insights analysis, and evidence dissemination.

But as AI adoption accelerates, the industry challenge is no longer simply identifying tools. The real challenge is determining which platforms can be deployed compliantly, responsibly, and effectively within the highly regulated environment of medical affairs.

As AI adoption accelerates across healthcare and life sciences, a broader industry conversation is emerging around AI governance, oversight, and accountability. While many organizations now offer AI education or implementation support, very few are focused specifically on establishing governance frameworks for AI use within medical affairs. This distinction is important. The future challenge for medical affairs organizations will not simply be identifying AI tools, but ensuring those tools are implemented responsibly, compliantly, and with appropriate scientific oversight. As a result, industry leaders are increasingly recognizing the need for standardized approaches to AI competency, governance evaluation, risk mitigation, and responsible deployment within regulated scientific environments. This is likely to become a defining area of focus for the next generation of medical affairs transformation.

At the Accreditation Council for Medical Affairs (ACMA), the Board Certified Medical Affairs Specialist (BCMAS) program and ACMA’s broader AI initiatives focus not only on understanding emerging technologies, but on helping medical affairs professionals develop the competencies and governance frameworks, including AI governance, required to evaluate, implement, and oversee AI responsibly.

This includes training medical affairs teams on:

• AI governance and oversight
• Compliant use of generative AI
• Scientific accuracy validation
• AI-supported KOL engagement strategies
• Medical information workflows
• Field medical intelligence analysis
• AI-assisted literature review and evidence synthesis
• Omnichannel scientific engagement

The platforms below represent notable examples of how AI is being integrated into medical affairs workflows in 2026. Rather than serving as endorsements or rankings, these examples illustrate the broader capability categories emerging across the industry and the strategic considerations medical affairs leaders should evaluate when assessing AI solutions.

AI-Powered HCP Engagement and Scientific Outreach

Impiricus Ascend

One of the most significant areas of AI adoption in medical affairs is intelligent HCP engagement. Platforms such as Impiricus Ascend are helping pharmaceutical organizations extend scientific communication beyond traditional in-person field engagement models.

Impiricus uses AI trained on billions of HCP data points to optimize physician engagement through compliant, opt-in communication channels. For medical affairs teams, this creates new opportunities to deliver scientific content to hard-to-reach physicians while generating actionable engagement analytics.

Medical affairs organizations evaluating these types of platforms should assess:

• Compliance oversight mechanisms
• Scientific content governance
• HCP consent and engagement transparency
• Explainability of AI-driven recommendations
• Integration with field medical workflows

Potential use cases include MSL reach extension, real-time dissemination of new clinical evidence, and physician-directed scientific engagement models.

AI for KOL Intelligence and Field Medical Planning

Veeva Link

KOL identification and scientific engagement planning remain core medical affairs functions. AI-powered platforms such as Veeva Link are increasingly being used to aggregate and synthesize large-scale scientific and professional data sources into dynamic expert profiles.

These systems support:

• KOL segmentation
• Territory planning
• Scientific influence mapping
• Congress preparation
• Emerging expert identification

As these capabilities evolve, medical affairs leaders must ensure that AI-driven KOL prioritization remains scientifically appropriate, transparent, and free from unintended bias. Governance around data sourcing, algorithmic transparency, and appropriate use of engagement analytics will become increasingly important as AI-guided field planning becomes more sophisticated.

AI-Powered Clinical Evidence Access and Scientific Exchange

OpenEvidence

The rapid adoption of clinical AI platforms such as OpenEvidence demonstrates how physicians themselves are increasingly incorporating AI into clinical decision support workflows.

For medical affairs teams, this creates an important strategic shift. Scientific exchange now increasingly occurs in an environment where physicians may already be using AI-generated evidence summaries prior to interacting with an MSL or medical information team.

This creates new considerations for medical affairs organizations:

• How evidence is surfaced within AI systems
• Accuracy and citation transparency
• Scientific consistency between internal and external platforms
• Monitoring visibility of company-supported evidence
• Alignment between AI outputs and approved scientific communication standards

Medical affairs teams may increasingly need competency frameworks focused on understanding how clinicians interact with AI-generated evidence and how scientific engagement strategies should adapt accordingly.

AI for Insights Management and Medical Strategy

Within3

Another major area of AI transformation is insights management. Platforms such as Within3 are increasingly helping organizations analyze information gathered through advisory boards, congresses, MSL interactions, and stakeholder engagements.

These systems can accelerate:

• Insight synthesis
• Stakeholder sentiment analysis
• Congress intelligence reporting
• Advisory board analytics
• Strategic planning workflows

However, the growing use of AI-generated insights also raises important governance questions:

• How are insights validated?
• What level of human oversight is required?
• How should AI-generated strategic recommendations be reviewed?
• How should organizations prevent hallucinated or misleading outputs from influencing medical strategy?

As AI increasingly influences strategic decision-making, governance processes become as important as the technology itself.

AI for HCP Data Intelligence and Engagement Precision

H1 for Medical

Data infrastructure has become foundational to modern medical affairs strategy. Platforms such as H1 for Medical are helping organizations integrate HCP activity data, publication history, clinical trial participation, and engagement analytics into unified intelligence systems.

These capabilities can support:

• Launch planning
• KOL engagement strategies
• Investigator identification
• Scientific territory optimization
• Evidence generation planning

But the increasing scale of AI-enabled HCP intelligence also requires organizations to carefully evaluate:

• Data accuracy
• Data provenance
• Privacy considerations
• Bias mitigation
• Appropriate use policies
• Governance oversight

As AI-powered targeting and engagement become more advanced, medical affairs leaders will need to ensure that scientific exchange remains credible, compliant, and patient-centered.

The Future of AI in Medical Affairs

The future of AI in medical affairs will not be determined solely by which platforms organizations adopt. It will be determined by which organizations build the governance structures, workforce competencies, scientific oversight processes, and ethical frameworks necessary to deploy AI responsibly.

The industry does not simply need more AI tools. It needs standardized approaches for evaluating, governing, and operationalizing AI within medical affairs.

The organizations that lead over the next decade will likely be those that combine:

• Scientific rigor
• Human expertise
• AI governance
• Responsible implementation
• Data integrity
• Medical affairs competency development

As AI continues reshaping scientific engagement, the role of medical affairs professionals may become even more strategically important, not less. The ability to interpret evidence, apply scientific judgment, ensure compliance, and build trusted relationships cannot be fully automated.

Instead, AI is becoming a force multiplier for organizations that know how to implement it responsibly.

Download Our "Understanding AI" Whitepaper Here!